Luxturna FDA Approval History
Last updated by Judith Stewart, BPharm on March 2, 2021.
FDA Approved: Yes (First approved December 19, 2017)
Brand name: Luxturna
Generic name: voretigene neparvovec
Dosage form: Intraocular Suspension for Subretinal Injection
Company: Spark Therapeutics, Inc.
Treatment for: Biallelic RPE65-Mediated Inherited Retinal Disease
Luxturna (voretigene neparvovec) is an adeno-associated viral (AAV) vector gene therapy for the treatment of patients with vision loss due to confirmed biallelic RPE65-mediated inherited retinal disease (IRD).
Development timeline for Luxturna
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.